IL-6 in BM supernatant as a predictor of poor chemotherapy outcomes in AML. (A) IL-6 levels in the BM supernatant of patients with AML stratified by ELN 2022 risk classification. (B) Receiver operating characteristic (ROC) curve of IL-6 in the BM supernatant for distinguishing between favorable- and adverse-risk AML groups. (C) Correlation between IL-6 levels in the BM supernatant and the BM blast clearance rate. (D) IL-6 levels in the BM supernatant of patients with AML with different chemotherapy efficacy. (E) ROC curve of IL-6 in the BM supernatant for distinguishing between ORR and NR groups. Data are presented as median with interquartile range. Differences analyzed using Kruskal-Wallis test with Dunn multiple comparisons test (A), area under the ROC curve (B,E), Spearman correlation (C), or Mann-Whitney test (D). ∗∗P < .01; ∗∗∗∗P < .0001. AUC, area under the curve; ns, not significant.
Figure 1.

IL-6 in BM supernatant as a predictor of poor chemotherapy outcomes in AML. (A) IL-6 levels in the BM supernatant of patients with AML stratified by ELN 2022 risk classification. (B) Receiver operating characteristic (ROC) curve of IL-6 in the BM supernatant for distinguishing between favorable- and adverse-risk AML groups. (C) Correlation between IL-6 levels in the BM supernatant and the BM blast clearance rate. (D) IL-6 levels in the BM supernatant of patients with AML with different chemotherapy efficacy. (E) ROC curve of IL-6 in the BM supernatant for distinguishing between ORR and NR groups. Data are presented as median with interquartile range. Differences analyzed using Kruskal-Wallis test with Dunn multiple comparisons test (A), area under the ROC curve (B,E), Spearman correlation (C), or Mann-Whitney test (D). ∗∗P < .01; ∗∗∗∗P < .0001. AUC, area under the curve; ns, not significant.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal